Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy
Our data confirmed the detrimental impact of a high NLR on survival and revealed the importance of monocyte levels in anti-tumor responses, providing useful information to physicians treating advanced NSCLC that may help tailor immunotherapy regimens and provide more accurate prognostic assessments.
Authors
- Ahmet Sezer (ORCID: https://orcid.org/0000-0002-6445-1439)
- Julie R. Brahmer (ORCID: https://orcid.org/0000-0002-2443-8395)
- Frank Seebach
- Miranda Gogishvili (ORCID: https://orcid.org/0000-0002-5143-6379)
- Tamar Melkadze (ORCID: https://orcid.org/0000-0003-0800-6514)
- Asha Pillai (ORCID: https://orcid.org/0000-0002-0488-3790)
- Jean‐François Pouliot (ORCID: https://orcid.org/0000-0002-9125-0456)
- Valsamo Anagnostou (ORCID: https://orcid.org/0000-0001-9480-3047)
- Rocío Acosta
- Joseph C. Murray (ORCID: https://orcid.org/0000-0001-6159-7814)
- Ana Baramidze (ORCID: https://orcid.org/0000-0003-3606-3268)
- Tamta Makharadze
- Petra Rietschel
- Alexander Meisel (ORCID: https://orcid.org/0000-0003-2422-1281)
- Young Il Kim (ORCID: https://orcid.org/0000-0001-6758-4344)
- Vladimir Janković (ORCID: https://orcid.org/0000-0002-4135-8629)
- Giuseppe Gullo (ORCID: https://orcid.org/0000-0001-5325-1055)
- Adam Y He
- Gregory P. Geba
- D. McIntyre
Institutions
- Johns Hopkins University (US)
- Regeneron (United States) (US)
- University of Zurich (CH)
- University Hospital of Zurich (CH)
- Medical Center Hospital (US)
- Sidney Kimmel Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100959
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00